HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: Impact on susceptibility to first-line strategies

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2084-2089

[No Author Info available]

Author keywords

HIV 1; Primary HIV infection; Resistance associated mutations

Indexed keywords

ETRAVIRINE; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; FEMALE; FRANCE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; NONHUMAN; PHYLOGENY; PREVALENCE; SEXUALLY TRANSMITTED DISEASE; VIRUS ISOLATION; VIRUS STRAIN;

EID: 84936948256     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv049     Document Type: Article

References (20)

1. Descamps D, Assoumou L, Chaix M-L et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother 2013; 68: 2626-31.
2. Yebra G, Delgado R, Pulido F et al. Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade. Arch Virol 2014; 159: 1079-87.
3. Sierra-Enguita R, Rodriguez C, Aguilera A et al. X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. AIDS 2014; 28: 1603-9.
4. UK Collaborative Group on HIV Drug Resistance. Dolling D, Sabin C et al. Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ 2012; 345: e5253.
5. Frentz D, van de Vijver D, Abecasis A et al. Patterns of transmitted HIV drug resistance in Europe vary by risk group. PloS One 2014; 9: e94495.
6. Colafigli M, Torti C, Trecarichi EM et al. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect 2012; 18: E299-304.
7. Monge S, Guillot V, Alvarez M et al. Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. Clin Microbiol Infect 2012; 18: E485-490.
8. Pineda-Peña A-C, Schrooten Y, Vinken L et al. Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic. PloS One 2014; 9: e101738.
9. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PloS One 2009; 4: e4724.
10. Lambert-Niclot S, Charpentier C, Storto A et al. Prevalence of preexisting resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. J Antimicrob Chemother 2013; 68: 1237-42.
11. Parczewski M, Urbańska A, Maciejewska K et al. Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland. J Int AIDS Soc 2014; 17: 18929.
12. Vingerhoets J, Rimsky L, Van Eygen Vet al. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response. Antivir Ther 2013; 18: 253-6.
13. Stekler JD, McKernan J, Milne R et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 2014; doi:10.3851/IMP2780.
14. Goujard C, BonarekM, Meyer L et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42: 709-15.
15. Bacchus C, Cheret A, Avettand-Fenoël Vet al. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PloS One 2013; 8: e64219.
16. Johnson VA, Calvez V, Gunthard HF et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013; 21: 6-14.
17. Groupe d'experts sous la direction du Pr Philippe Morlat et sous l'égide du CNS et de l'ANRS. Prise en charge médicale des personnes vivant avec le VIH. Actualisation 2014 du rapport 2013. Available at: http://www.sante.gouv.fr/IMG/pdf/experts-vih_actualisations2014.pdf.
18. Günthard HF, Aberg JA, Eron JJ et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312: 410-25.
19. Chaix M-L, Descamps D, Wirden M et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009; 23: 717-24.
20. Vercauteren J, Wensing AMJ, van de Vijver DAMC et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.